Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer
Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.
Source: onclive.com